Clinical Trials Logo

Clinical Trial Summary

This is a single center, open-labeled, single arm phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients unsuitable for intravenous chemotherapy.


Clinical Trial Description

Fruquintinib is an oral small molecule inhibitor of VEGFR1/2/3, this phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients of elderly or those unsuitable for intravenous chemotherapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04866108
Study type Interventional
Source Beijing Friendship Hospital
Contact Zhigang Bai
Phone +86-010-63138712
Email [email protected]
Status Recruiting
Phase Phase 2
Start date April 2021
Completion date June 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03692429 - alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells Phase 1
Completed NCT01802684 - OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer Phase 2
Not yet recruiting NCT04131803 - Probiotics Combined With Standard Chemotherapy Plus Targeted Therapy in Patients With Metastatic Colorectal Cancer N/A
Recruiting NCT04160416 - mXELOXIRI Combined With Molecular Targeted Drug in mCRC Phase 2